The 2020 update of the Canadian stroke best practice recommendations CSBPR for secondary prevention of stroke advises that, for patients with stroke and type 2 DM who do not reach glycemic targets with standard oral medications, antihyperglycemic agents shown to improve major cardiovascular outcomes, such as SGLT-2 inhibitors or GLP-1 RAs, should be considered as part of the treatment strategy [107]. The gene discussed is SLC5A2; the disease is Stroke.